The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes
Rebecca C. Coll(Queen's University Belfast), Luke O'neill(Trinity College Dublin)
Cited by 136
Related Papers
Metabolic reprogramming in macrophages and dendritic cells in innate immunity
|Cell Research|2015|1.8k
MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
|Nature Chemical Biology|2019|975
Targeting Toll-like receptors: emerging therapeutics?
|Nature Reviews Drug Discovery|2010|883
Trained immunity, tolerance, priming and differentiation: distinct immunological processes
|Nature Immunology|2020|591
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
|Cell Metabolism|2020|571